Always refreshing to hear from another specialist's point of view Cardiologist @Bweber04 on CVD and rheumatologic diseases Increased risk of death, MI and HF exacerbation in our pt population Increased all cause mortality @RheumNow #ACR23 https://t.co/yOkPOmxU4N

@Bweber04 on recurrent pericarditis especially some seen in our lupus population IL-1 inhibition with Rilonacept really redefining treatment success and altering the typical treatment algorithm @RheumNow #ACR23 https://t.co/Ey1DN8eSXT

Later today at #ACR23 at 4pm See Ab#2545 on IV secukinumab for AxSpA Read about it now on @RheumNow: https://t.co/s9IinpVxgR

RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Watch: Ultrasound for PsA Stratification: Are We There Yet? Dr. Aurelie Najm reports live from #ACR23 https://t.co/TnDVbKXcd4 https://t.co/RTbjL2wbUj

• Ultrasound for PsA Stratification: Are We There Yet? | RheumNow

Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs No change in utilization rates post black box... maybe people had already baked this into the cake by then? @RheumNow #ACR23 Abstr 2142 https://t.co/K9cWbRSWV6

Amazing & thoughtful poster re:protocol violates in TICOSPA trial 51.2% of pts violated T2T protocol at least once... but did not impact primary outcome Good baseline for future "strategy" style pragmatic trials @RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP

#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT

A#L09 #ACR23 @RheumNow New JAK! LNK01001 Chinese pts with mod-severe RA, csDMARD failures 12mg/24mg/PBO: W12: ACR20 60/73/31%, ACR50 40/42/9, ACR70 12/21/2% Stat signif diff reached at wk 1 for ACR20! Improved DAS28, HAQ-DI Wk24 ext: 91% remain in ACR 20 AEs: HLD noted https://t.co/RXOMzxGOTy

CV Events in AS by Rx A#L11 @RheumNow #ACR23 43K pts from Korean data Rates of incident MI or CV: 18.7 per 10,000 py in non-bDMARD pt 8.9 in TNF 12.9 in IL-17 TNFi reduced risk of CVD HR 0.7, not signif for IL-17 Supports idea of TNFi giving a cardioprotective effect? #ACRBest https://t.co/SvVVDSU23z

ARTIC REWIND: To taper or not? A#L07 #ACR23 @RheumNow RA pts taper TNFi in stable remission No taper group: 85% flare free in 3 yrs Taper grp: only 25% Lower Boolean 2.0 Remission rates Don't taper off a good thing! https://t.co/KnJrEfVFkV

Lessons for #CVD in #inflammatory #rheumatic #diseases #ACR23 @RheumNow @ACRheum #ACRbest -Negative #coronary #calcification doesn’t r/o presence of #microvascular #dysfunction - work w #cardiologist for@proper@imaging for #Dx -for #CAD or #pericarditis #Colchicine is GOOD https://t.co/dMO1FpoA2a

Excellent session: Navigating CV risk for #inflammatory #arthritis - view from #cardiology #ACR23 14T118 @RheumNow @ACRheum https://t.co/WKhh0TonE8